Brokerages Set Insulet Corporation (PODD) PT at $50.20
Insulet Corporation (NASDAQ:PODD) has been assigned a consensus rating of “Buy” from the eighteen analysts that are covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $50.20.
Several equities analysts have weighed in on PODD shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $58.00 target price (up previously from $48.00) on shares of Insulet Corporation in a research note on Wednesday, August 9th. BidaskClub raised Insulet Corporation from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 27th. Canaccord Genuity reaffirmed a “hold” rating and set a $42.00 target price on shares of Insulet Corporation in a research note on Friday, May 26th. Cowen and Company reaffirmed a “buy” rating and set a $52.00 target price on shares of Insulet Corporation in a research note on Friday, July 14th. Finally, ValuEngine raised Insulet Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd.
Insulet Corporation (NASDAQ PODD) traded down 1.49% during trading on Tuesday, hitting $57.00. 61,524 shares of the stock traded hands. Insulet Corporation has a 52-week low of $30.69 and a 52-week high of $58.48. The company’s 50 day moving average price is $52.55 and its 200-day moving average price is $46.04. The stock’s market cap is $3.31 billion.
Insulet Corporation (NASDAQ:PODD) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The company had revenue of $110 million for the quarter, compared to analysts’ expectations of $106.23 million. During the same quarter in the previous year, the business posted ($0.08) EPS. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. Equities research analysts forecast that Insulet Corporation will post ($0.50) earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of PODD. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Insulet Corporation by 11.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock valued at $118,000 after buying an additional 235 shares during the period. Strs Ohio raised its stake in Insulet Corporation by 73.9% in the first quarter. Strs Ohio now owns 4,000 shares of the medical instruments supplier’s stock valued at $172,000 after buying an additional 1,700 shares during the period. SG Americas Securities LLC bought a new stake in Insulet Corporation during the second quarter valued at $180,000. Teacher Retirement System of Texas bought a new stake in Insulet Corporation during the first quarter valued at $201,000. Finally, Diversified Trust Co bought a new stake in Insulet Corporation during the second quarter valued at $205,000.
TRADEMARK VIOLATION WARNING: “Brokerages Set Insulet Corporation (PODD) PT at $50.20” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/25/brokerages-set-insulet-corporation-podd-pt-at-50-20.html.
About Insulet Corporation
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Stock Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related stocks with our FREE daily email newsletter.